Bespak signs new development agreement with Innovata Biomed

Published: 1-Jul-2004

UK drug delivery specialist Bespak has signed a key new development agreement with inhalation technology company Innovata Biomed (IB), the respiratory division of ML Laboratories, which supplies inhaled drug delivery technologies to the pharmaceutical industry.


UK drug delivery specialist Bespak has signed a key new development agreement with inhalation technology company Innovata Biomed (IB), the respiratory division of ML Laboratories, which supplies inhaled drug delivery technologies to the pharmaceutical industry.

Under the terms of the agreement Bespak will develop IB's novel new C200 multidose dry powder inhaler device for the delivery of combination drug therapies for diseases such as asthma. Bespak will also supply IB with clinical trial quantities of devices.

In a separate announcement ML Laboratories disclosed that IB has entered into an exclusive multi-million pound licence agreement with an undisclosed major global pharmaceutical group to market and distribute the new C200 inhaler in Europe.

  

You may also like